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Background: Ezetimibe may be more effective in patients with high cholesterol absorption than in patients with
low cholesterol absorption. This prospective study was performed to evaluate the effect of ezetimibe on hyper-
cholesterolemia in patients with metabolic syndrome (MetS).
Methods and results: 81 patients with hypercholesterolemia in the presence or absence of MetS (MetS or non-
MetS group) initially received ezetimibe (10 mg/day). In both groups, the levels of total cholesterol (TC), triglyc-
eride, low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C) and
the ratio of LDL-C to HDL-C (L/H) signiﬁcantly decreased with treatment. A ratio of lathosterol to TC
(lathosterol/TC) in the MetS group was signiﬁcantly higher than that in the non-MetS group before treatment.
Lathosterol/TC signiﬁcantly increased after treatment in both groups, and campesterol/TC and sitosterol/TC signif-
icantly decreased. The non-MetS group, but not the MetS group, showed a signiﬁcant increase in cholesterol/TC
after treatment. Finally, we divided all of the patients into two groups (responders and non-responders)
according to the percent changes in LDL-C after treatment. Male gender (p = 0.037), the presence of MetS
(p = 0.026) and lower levels of L/H (p = 0.006)were independent factors that predicted a response to ezetimibe.
Conclusions: The lipid-lowering effect of ezetimibe in MetS was comparable to that in non-MetS. Treatment with
ezetimibe may be effective in males with MetS and relatively lower levels of L/H.© 2013 The Authors. Published by Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.Introduction
Low cholesterol absorption has been associated with a lower rate of
total mortality [1]. Impaired cholesterol homeostasis, reﬂected by lower
cholesterol synthesis and higher concentrations of absorption markers,
is a highly signiﬁcant independent predictor of the presence of coronary
artery disease (CAD) in participants in the FraminghamOffspring Study
[2]. In addition, CAD patients with a high rate of cholesterol absorption
did not beneﬁt from statin therapy, while those with low absorption
showed a reduction in coronary events [3].
Ezetimibe selectively inhibits dietary and biliary cholesterol absorp-
tion into the intestine by binding to the Niemann–Pick C1 like 1
(NPC1L1) protein [4,5] at the brush-border membrane of enterocytes,
and is widely used for the treatment of dyslipidemia (DL). Ezetimibe at, Fukuoka University School of
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land Ltd. Open access under CC BY-NC10 mg/day induced a nearly 20% reduction in low-density lipoprotein
cholesterol (LDL-C) [6,7]. In patients with primary DL, ezetimibe
(10 mg/day) therapy for 16 weeks reduced total cholesterol (TC), LDL-
C and non-high-density lipoprotein cholesterol (non-HDL-C) values as
well as the apolipoprotein (apo) B concentration [8]. In addition,
ezetimibe improves endothelial function [9,10] and decreases coronary
atheromavolume [11,12]. Although there are nodata available regarding
the efﬁcacy of ezetimibe alone in reducing CAD events, pharmacological
intervention using ezetimibe through the inhibition of intestinal choles-
terol absorption may be a useful strategy for treating patients with DL
and/or CAD.
Metabolic syndrome (MetS),which is a cluster of abdominal obesity,
DL, hypertension (HT) and glucose intolerance, is associated with a
2-fold increase in CAD [13]. Cholesterol metabolism, in patients with
MetS, insulin resistance and abdominal obesity and/or diabetes, generally
exhibits a pattern of low cholesterol absorption and high cholesterol syn-
thesis [14–19]. Compared with controls, patients with MetS had signiﬁ-
cantly lower campesterol levels and higher lathosterol levels [14].
Hemodialysis (HD) patients showed lower cholesterol concentrations
than non-HD patients, and, as a compensation, their cholesterol absorp-
tion might be accelerated [20]. Cholesterol synthesis was signiﬁcantly
higher and absorption was signiﬁcantly lower in patients with diabetes
mellitus (DM) compared with controls [19]. In addition, low cholesterol
absorption is an indicator of insulin resistance, which presumably links-ND license.
Table 1





Age (yrs.) 62 ± 11 62 ± 11
Male (%) 62 38
BMI (kg/m2) 27 ± 4⁎ 25 ± 3
Abdominal circumference (cm) 94 ± 8⁎⁎ 88 ± 9
DM (%) 69 24
HT (%) 90 86
Serum parameter
Total cholesterol (mg/dl) 253 ± 30 240 ± 34
LDL-C (mg/dl) 173 ± 29 163 ± 29
HDL-C (mg/dl) 53 ± 12 55 ± 12
TG (mg/dl) 176 ± 67⁎ 137 ± 66
Non HDL-C (mg/dl) 198 ± 30 185 ± 16
RLP-C (mg/dl) 8.6 ± 3.8⁎ 6.1 ± 3.4
Macromolecule adiponectin (wg/rnl) 4.6 ± 2.3 6.3 ± 5.0
Highly sensitive CRP (mg/dl) 0.103 ± 0.098 0.096 ± 0.094
Lathosterol (pg/ml) 4.32 ± 1.4⁎⁎ 3.21 ± 1.4
Campesterol (pg/ml) 5.18 ± 2.2 4.84 ± 1.8
Sitosterol (wg/rnl) 3.02 ± 1.2 3.17 ± 1.2
Cholesterol (wg/rnl) 3.06 ± 0.6 2.97 ± 0.6
Lathosterol/TC (×l0−5) 1.73 ± 0.57⁎ 1.34 ± 0.54
Campesterol/TC (×10−5) 2.04 ± 0.82 2.05 ± 0.86
Sitosterol/TC (×10−5) 1.20 ± 0.43 1.34 ± 0.53
Cholesterol/TC (×10−5) 1.21 ± 0.21 1.23 ± 0.26
The values represent mean ± SD. BMI, body mass index; DM, diabetes mellitus; HT, hy-
pertension; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein
cholesterol; TG, triglyceride; RLP-C, remnant like particle cholesterol; CRP, C-reactive
protein; TC, total cholesterol.
⁎ p b 0.05 vs. non-MetS group.
⁎⁎ p b 0.01 vs. non-MetS group.
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receptor, which can upregulate cholesterol-synthesis genes [21].
Ezetimibe therapy has been associated with a reduction in
campesterol and an increase in lathosterol [22,23]. Treatment with
ezetimibe decreased the campesterol/lathosterol ratio, and the change
in this ratio was directly associated with the LDL-C response [22].
Ezetimibe should be more effective in patients with high cholesterol ab-
sorption than in patientswith lowcholesterol absorption. Thus, although
it is possible to reduce the incidence of CAD by ezetimibe therapy, we
examined whether ezetimibe is effective in MetS patients who were
characterized as having low cholesterol absorption.
Therefore, we prospectively evaluated the effect of ezetimibe on
hypercholesterolemia in the lipid proﬁle with or without MetS. We
also analyzed whether ezetimibe is more efﬁcient in patients with
high cholesterol absorption.
Methods
Subjects and study design
This trial was conducted at the Fukuoka University Hospital and its
related hospitals in the Kyushu area of Japan (total of 13 hospitals;
Appendix 1). The protocol was approved by the Independent Review
Board (IRB) of the Fukuoka University Hospital. Each subject signed an
informed consent form after the protocol was explained. Patients
with or without MetS were administered ezetimibe (10 mg/day) for
16 weeks. Age, sex, pre-treatment with statins, and patient category
according to the Japan Atherosclerosis Society (JAS) Guidelines for the
Diagnosis and Treatment of Atherosclerotic Cardiovascular Diseases
[24] were equally distributed between the MetS and non-MetS groups
by computer randomization entrusted to Medical Bio Informatics,
Tokyo. A diagnosis of MetS was based on abdominal circumference
(≥85 cm inmales,≥90 cm in females) and at least two of the following
criteria: systolic blood pressure (BP) ≥130 mm Hg and/or diastolic BP
≥85 mm Hg, HDL-C b40 mg/dl and/or triglyceride (TG) ≥150 mg/dl,
and fasting blood sugar N110 mg/dl.
The primary endpoint was the percent change in LDL-C levels in the
MetS and non-MetS groups. Secondary endpoints were the percent
changes in remnant-like lipoprotein cholesterol (RLP-C), TG, HDL-C,
small-dense LDL-C, highly sensitive C-reactive protein (hs-CRP),
adiponectin, markers of cholesterol synthesis and absorption before
and after treatment with ezetimibe in the MetS and non-MetS groups.
For safety, secondary endpoints included the adverse drug reaction
rate and the abnormal variation rate in clinical laboratory tests.
Eighty-one patients with hypercholesterolemia with or without
MetS were enrolled from January 2009 to August 2011. A subject was
eligible for inclusion if they satisﬁed the following criteria: LDL-C
≥140 mg/dl, or they had not reached the target LDL-C levels recom-
mended by the JAS Guidelines [24], aged N20 years. The pre-existing
administration of statins, if any, was discontinued for at least 4 weeks.
A subject was not eligible for inclusion if they met any of the following
criteria: 1) TG N500 mg/dl at baseline, 2) moderate to severe liver
dysfunction, 3) acute coronary syndrome (unstable angina and acute
myocardial infarction), old myocardial infarction excluding stable angi-
na pectoris, asymptomatic coronary stenosis by coronary CT, heart fail-
ure and acute cerebrovascular disease, 4) uncontrolled type 2 diabetes
mellitus (HbA1c N8.5%), 5) previous drug allergy (shock, anaphylactic
symptom, blood vessel edema), 6) taking an anti-autoimmune
drug, 7) familial or secondary hypercholesterolemia, 8) pregnancy
or lactation in women, and 9) alcohol abuse.
Measurements
BP and pulse rate were measured every month during the trial peri-
od. Serum levels of LDL-C, TG, HDL-C, complete blood count, urinalysis,
biochemistry including aspartate aminotransferase (AST), alanineaminotransferase (ALT), creatinine, creatine kinase, hemoglobin A1c,
hs-CRP, adiponectin, apo A-I, apo B, and other lipoprotein proﬁles
weremeasured everymonth during the trial period at the FukuokaUni-
versity Hospital Laboratory Unit or by the SRL Corporation.
Statistical analysis
All of the data analyses were performed using the SAS software
package (version 9.2; SAS Institute) at Fukuoka University (Fukuoka,
Japan). Frequency distributions for categorical variables were compared
among (between) groups using the chi-squared analysis and/or Fisher's
exact test. Differences in continuous variables among (between)
groups were examined using analysis of variance (ANOVA). Contin-
uous variables during the study period are presented as mean ± SD,
and the changes and percentage changes in continuous variables
during the study period are given as median values. Multivariate
analysis was performed by a logistic regression analysis for indepen-
dent variables that were related to the response or lack of response
to ezetimibe treatment. Signiﬁcance was set at p b 0.05 unless other-
wise indicated.
Results
Baseline clinical characteristics in the MetS and non-MetS groups
Three of the 81 subjects did not meet the enrollment criteria:
2 showed high levels of hs-CRP, and 1 had a TG level N500 mg/dl.
During the follow-up period, 20 patients dropped out and had lacking
of biochemical data. Thus, 29 MetS patients (18 males and 11 females,
mean age: 62 y) and 29 non-MetS subjects (11 males and 18 females,
mean age: 62 y) were included in the further analysis. Table 1 shows
the baseline clinical characteristics in the MetS and non-MetS groups.
69% and 24% of the patients in the MetS and non-MetS groups, respec-
tively, had DM. 90% and 86% of the patients in the MetS and non-MetS
groups, respectively, had HT. BMI, abdominal circumference, TG and
9N. Kumagai et al. / IJC Metabolic & Endocrine 1 (2013) 7–12RLP-C in the MetS group were signiﬁcantly higher than those in the
non-MetS group.
Time-course of the lipid proﬁle under treatment with ezetimibe in the MetS
and non-MetS groups
Changes in the lipid proﬁle after treatment with ezetimibe in the
MetS and non-MetS groups are shown in Fig. 1. In both the MetS and
non-MetS groups, the levels of TC, TG, LDL-C, non-HDL-C and the ratio
of LDL-C to HDL-C (L/H) showed signiﬁcant reductions after treatment.
There were no changes in the HDL-C level in either group.
Changes in the sterol/TC ratios after treatment with ezetimibe in the MetS
and non-MetS groups
Fig. 2 shows the changes in the sterol/TC ratios after treatment with
ezetimibe in the MetS and non-MetS groups. Lathosterol/TC in the
MetS group was signiﬁcantly higher than that in the non-MetS group
before treatment, whereas there were no signiﬁcant differences in
campesterol/TC, sitosterol/TC, or cholesterol/TC between the MetS
and non-MetS groups before treatment. Lathosterol/TC was signiﬁcantly
increased after treatment in both groups, and campesterol/TC and
sitosterol/TC were signiﬁcantly decreased. The non-MetS group, but
not the MetS group, showed a signiﬁcant increase in cholesterol/TC
after treatment.
Differences in baseline clinical characteristics in responders, moderate-
responders, mild-responders and non-responders after ezetimibe treatment
in the MetS group
Next, we divided the patients in the MetS group into quartiles ac-
cording to the percent change in LDL-C after ezetimibe treatment
(%ΔLDL-C) (Table 2). %ΔLDL-C was calculated as 100× (LDL-C level
after treatment − LDL-C level before treatment / LDL-C level beforeFig. 1. Time-course of the lipid proﬁle under 16 weeks of treatment with ezetimtreatment). %ΔLDL-C in the responders, moderate-responders, mild-
responders and non-responders was −34.5 ± 5.3, −25.6 ± 1.6,
−19.6 ± 2.7 and−6.2 ± 13.5%, respectively. There were no differ-
ences in the baseline clinical characteristics between these groups.
Differences in baseline clinical characteristics in responders, moderate-
responders, mild-responders and non-responders after ezetimibe treatment
in the non-MetS group
Next, we divided the patients in the non-MetS group into quar-
tiles according to %ΔLDL-C (Table 3). %ΔLDL-C in the responders,
moderate-responders, mild-responders and non-responders was
−30.1 ± 4.5, −19.6 ± 3.2, −13.3 ± 2.0 and−3.4 ± 5.3%, respec-
tively. Responders showed signiﬁcantly lower levels of adiponectin
and higher lathosterol/TC ratios than non-responders.
Factors that contributed to a response to treatment with ezetimibe
Finally, we divided all of the patients into two groups (responders
and non-responders) according to %ΔLDL-C (Table 4). Male gender
(p = 0.037), the presence of MetS (p = 0.026) and lower levels of
L/H (p = 0.006) were independent factors that predicted a response
to ezetimibe treatment.
Discussion
In this study, the lipid-lowering effect of ezetimibe in theMetS group
was comparable to that in the non-MetS group. TheMetS group showed
higher cholesterol synthesis but not lower cholesterol absorption before
treatment. After treatment, lathosterol/TCwas signiﬁcantly increased in
both groups, and campesterol/TC and sitosterol/TC were signiﬁcantly
decreased. Finally, male gender, the presence of MetS and relatively
lower levels of L/H at baseline were independent factors that predicted
a response to ezetimibe treatment.ibe in the MetS (a, c) and non-MetS groups (b, d). *p b 0.001 vs. 0 week.
Fig. 2. Changes in the sterol/TC ratio treatment with ezetimibe in theMetS and non-MetS groups. Open and closed bars indicate baseline and after 16 weeks of treatment with ezetimibe,
respectively. *p b 0.05, **p b 0.01, ***p b 0.001 vs. baseline in each group; tp b 0.05 vs. baseline in the non-MetS group; +p b 0.05 vs.16 weeks in the non-MetS group.
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LDL-C, non-HDL and L/H, were similar in the MetS and non-MetS
groups. In addition, ezetimibe treatment signiﬁcantly decreased
markers of cholesterol absorption in both groups and increased amark-
er of cholesterol synthesis. The present data regarding the baseline
characteristics of DL patients with or without MetS are comparable to
those in previous studies [14–19]. Our data also support the notion
that ezetimibe selectively inhibits cholesterol absorption and is associ-
ated with a rebound increase in cholesterol synthesis [25].Table 2
Differences in baseline clinical characteristics in responders, moderate-responders, mild-respo
Clinical characteristics Responders Moderate-responder
Changes in LDL-C (%) −34.5 ± 5.3 −25.6 ± 1.6
Members 7 7
Male:Female (male, %) 5:2 (71%) 4:3 (57%)
Age (yrs.) 66 ± 7 64 ± 10
BMI (kg/m2) 26 ± 3 29 ± 4
Abdominal circumference (cm) 91 ± 3 96 ± 13
HT (%) 5/7 (71%) 7/7 (100%)
DM (%) 6/7 (%) 2/7 (%)
Macromolecule adiponectin (wg/rnl) 5.41 ± 2.54 5.11 ± 2.29
hs-CRP (mg/dl) 0.048 ± 0.033 0.104 ± 0.038
TC (mg/dl) 248.6 ± 35.8 247.7 ± 32.1
LDL-C (mg/dl) 167.7 ± 32.8 165.3 ± 21.6
HDL-C (mg/dl) 53.4 ± 10.6 56.9 ± 11.2
TG (mg/dl) 179.3 ± 55.5 149.6 ± 66.5
Non-HDL-C (mg/dl) 195.1 ± 31.1 190.9 ± 27.2
L/H 3.17 ± 0.43 2.97 ± 0.45
Lathosterol/TC (×10−5) 1.7 ± 0.5 1.7 ± 0.6
Campesterol/TC (×10−5) 2.3 ± 1.2 2.0 ± 0.8
Sitosterol/TC (×10−5) 0.4 ± 0.6 1.2 ± 0.4
Cholesterol/TC (×10−5) 1.2 ± 0.2 1.3 ± 0.2
The values representmean ± SD. LDL-C, low-density lipoprotein cholesterol; BMI, bodymass in
TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride.Some of the patients in both groups did not show a lipid-lowering
response to ezetimibe. In the non-MetS group, the responders showed
lower levels of adiponectin and higher levels of lathosterol/TC com-
pared to non-responders, whereas there were no differences between
the responders and non-responders in the MetS group. Adiponectin is
a hormone secreted by adipocytes that plays a key role as an anti-
diabetic and anti-atherogenic adipokine [26]. Patients with obesity,
insulin resistance, and/or MetS have been shown to have lower
adiponectin levels [27]. Non-MetS patients showed normal levels ofnders and non-responders after ezetimibe treatment in the MetS group.
s Mild-responders Non-responders p value Res. vs Non-Res.
−19.6 ± 2.7 −6.2 ± 13.5
8 7
6:2 (75%) 3:4 (43%)
54 ± 15 62 ± 5 0.326
28 ± 3 27 ± 4 0.802
96 ± 10 94 ± 6 0.368
8/8 (100%) 6/7 (86%)
6/8 (%) 6/7 (%)
5.00 ± 2.26 3.07 ± 1.44 0.055
0.104 ± 0.098 0.157 ± 0.154 0.112
266.2 ± 30.5 248.4 ± 24.9 0.993
188.9 ± 33.2 166.6 ± 26.0 0.944
56.9 ± 12.5 44.0 ± 11.3 0.284
177.6 ± 78.4 195.4 ± 70.5 0.363
190.9 ± 27.2 204.4 ± 21.8 0.530
3.44 ± 0.81 3.94 ± 0.95 0.074
1.7 ± 0.5 1.8 ± 0.8 0.856
2.0 ± 0.6 1.9 ± 0.7 0.461
1.2 ± 0.3 1.0 ± 0.5 0.293
1.1 ± 0.2 1.2 ± 0.3 0.783
dex; HT, hypertension; DM, diabetesmellitus; hs-CRP, highly-sensitive C-reactive protein;
Table 3
Differences in baseline clinical characteristics in responders, moderate-responders, mild-responders and non-responders after ezetimibe treatment in the non-MetS group.
Clinical characteristics Responders Moderate-responders Mild-responders Non-responders p value Res. vs. Non-Res.
Changes in LDL-C (%) −30.1 ± 4.5 −19.6 ± 3.2 −13.3 ± 2.0 −3.4 ± 5.3
Members 7 7 8 7
Male:Female (male, %) 4:3 (57%) 2:5 (29%) 3:5 (38%) 2:5 (29%)
Age (yrs.) 56 ± 12 68 ± 12 61 ± 5 61 ± 14 0.536
BMI (kg/m2) 26 ± 2 24 ± 4 25 ± 3 26 ± 6 0.823
Abdominal circumference (cm) 92 ± 7 87 ± 7 83 ± 7 91 ± 14 0.906
HT (%) 5/7 (71%) 6/7 (86%) 8/8 (100%) 5/7 (71%)
DM (%) 2/7 (29%) 2/7 (29%) 3/8 (38%) 1/7 (14%)
Macromolecule adiponectin (pg/ml) 3.10 ± 1.41 7.69 ± 4.37 5.93 ± 6.01 8.69 ± 5.81 0.029
hs-CRP (mg/dl) 0.100 ± 0.014 0.122 ± 0.107 0.101 ± 0.065 0.059 ± 0.041 0.500
TC (mg/dl) 240.7 ± 23.2 244.3 ± 32.6 249.3 ± 48.9 225.7 ± 22.0 0.238
LDL-C (mg/dl) 166.9 ± 18.0 172.4 ± 23.1 167.8 ± 40.3 144.9 ± 27.1 0.099
HDL-C (mg/dl) 59.1 ± 8.2 55.7 ± 10.8 51.0 ± 15.5 54.4 ± 13.8 0.451
TG (mg/dl) 116.1 ± 29.7 124.1 ± 59.3 152.3 ± 90.8 151.4 ± 70.5 0.246
Non-HDL-C (mg/dl) 181.6 ± 21.2 188.6 ± 27.6 198.3 ± 56.7 171.3 ± 26.1 0.434
L/H 2.88 ± 0.57 3.18 ± 0.66 3.84 ± 2.46 2.79 ± 0.74 0.805
Campesterol/TC (×10−5) 1.8 ± 0.3 1.9 ± 0.6 2.2 ± 1.0 2.3 ± 1.3 0.293
Sitosterol/TC (×10−5) 1.1 ± 0.2 1.4 ± 0.4 1.4 ± 0.7 1.6 ± 0.7 0.096
Cholesterol/TC (×10−5) 1.1 ± 0.1 1.2 ± 0.3 1.2 ± 0.2 1.4 ± 0.3 0.073
Lathosterol/TC (×10−5) 1.6 ± 0.5 1.2 ± 0.4 1.5 ± 0.7 1.0 ± 0.3 0.031
The values representmean ± SD. LDL-C, low-density lipoprotein cholesterol; BMI, bodymass index; HT, hypertension; DM, diabetesmellitus; hs-CRP, highly-sensitive C-reactive protein;
TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride.
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though the patients in the non-MetS group did not match the criteria
ofMetS, the respondersmay have a background of ametabolic disorder,
such as insulin resistance, since 86% of these patients had HT. On the
other hand, since the MetS group showed lower adiponectin levels be-
cause of the accumulation of visceral fat compared to the non-MetS
group, there was no association between adiponectin levels and the ef-
fect of ezetimibe in theMetS group. Interestingly, in theMetS group, the
responders tended to show higher adiponectin levels than non-
responders. The reason for this discrepancy is not yet clear. Moreover,
cholesterol synthesis, such as that reﬂected by lathosterol levels, has
been shown to be increased in MetS and obesity [14–19]. In the non-
MetS group, the responders showed higher basal levels of lathosterol/
TC than non-responders. On the other hand, the lathosterol level did
not predict the response to ezetimibe in theMetS group. This difference
may be due to the relatively higher lathosterol/TC ratios in the MetS
group compared to the non-MetS group. The lathosterol/TC ratio in
males was signiﬁcantly higher than that in females in the present
study (p = 0.001). In fact, when we divided all of the patients into
two groups (responders and non-responders) according to %ΔLDL-C,
male gender and the presence of MetS were independent factors that
predicted a response to ezetimibe treatment. Finally, a lower L/H ratio
was the strongest independent factor that predicted a response to
ezetimibe treatment. Although markers of cholesterol absorption and
synthesis were not associated with a response to treatment, patients
with a lower L/H ratio showed signiﬁcantly higher sitosterol/TC valuesTable 4
Factors that contributed to a response to treatment with ezetimibe.
Factors OR (95% CI) p value
Age 0.98 (0.91–1.05) 0.500
Male 6.70 (1.12–40.0) 0.037
BMI 1.12 (0.88–1.43) 0.370
MetS (+) 6.71 (1.26–35.7) 0.026
L/H 0.15 (0.04–0.59) 0.006
Campesterol/TC 0.16 (0.01–0.20) 0.152
Sitosterol/TC 6.17 (0.13–287) 0.353
Cholesterol/TC 1.49 (0.04–57.0) 0.829
Lathosterol/TC 1.06 (0.27–4.13) 0.932
BMI, body mass index; MetS, metabolic syndrome; L/H, a ratio of LDL-cholesterol to HDL-
cholesterol; TC, total cholesterol; OR, odds ratio; CI, conﬁdence interval.(p = 0.021) and tended to show higher campesterol/TC (p = 0.05)
values than patients with a higher L/H ratio.
In this study, ezetimibe monotherapy signiﬁcantly reduced LDL-C
levels by about 19% along with plasma levels of cholesterol-absorption
markers, andmay promote a compensatory increase in cholesterol syn-
thesis with clinically relevant reductions in LDL-C. LDL-C levels at
16 weeks in the MetS and non-MetS groups were 136 mg/dl and
136 mg/dl, respectively. In addition, L/H levels were 2.62 and 2.48, re-
spectively. Since 24% and 86% of the subjects in the non-MetS group
had DM and HT, respectively, and since the co-administration of
ezetimibe and statins signiﬁcantly decreased LDL-C levels in addition
to plasma concentrations of both absorption and synthesis markers
[28,29], we should consider a combination therapy with ezetimibe
and statins.
This study has several limitations. First, the number of patients was
relatively small. Second, naturally occurring coding mutations in the
NPC1L1 gene might affect the response to ezetimibe. For example, dif-
ferent NPC1L1 protein variants (Val55 to Lue55 and Ile1233 to Asp1233)
have been found in a non-responder to ezetimibe [30]. The characteriza-
tion of DNA variations in NPC1L1 demonstrated that common variants
in this gene are signiﬁcantly associated with the response of LDL-C
levels to treatment with ezetimibe/statin [31]. Although there is some
evidence of an association between the LDL-C concentration and
NPC1L1 gene production as a target for ezetimibe, we did not analyze
the variations of the NPC1L1 gene in this study. Third, we measured
abdominal circumference, but not the visceral fat area.
In conclusion, cholesterol synthesis and absorption are interrelated
and play a crucial role in regulating cholesterol homeostasis. Although
the homeostasis of features related to MetS is characterized by high
levels of cholesterol synthesizers, the lipid-lowering effect of ezetimibe
in the MetS group was comparable to that in the non-MetS group. In
particular, ezetimibe treatment may be effective in males with MetS
and relatively lower levels of L/H.
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